Literature DB >> 10541323

Correction of ureagenesis after gene transfer in an animal model and after liver transplantation in humans with ornithine transcarbamylase deficiency.

M L Batshaw1, M B Robinson, X Ye, C Pabin, Y Daikhin, B K Burton, J M Wilson, M Yudkoff.   

Abstract

We report effects of gene transfer and liver transplantation on urea synthesis in ornithine transcarbamylase deficiency (OTCD). We measured the formation of [15N] urea after oral administration of 15NH4Cl in two girls with partial OTCD before and after liver transplantation. Ureagenesis was less than 20% of that observed in controls before transplantation, and was normalized afterward. Studies performed on the OTCD sparse fur (spf/Y) mouse showed discordance between OTC enzyme activity and ureagenesis with modest increases in OTC enzyme activity after gene transfer resulting in significant improvement in ureagenesis. This study suggests that both liver transplantation and gene therapy may be effective in improving ureagenesis in OTCD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10541323     DOI: 10.1203/00006450-199911000-00016

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  2 in total

1.  AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice.

Authors:  Sharon C Cunningham; Afroditi Spinoulas; Kevin H Carpenter; Bridget Wilcken; Philip W Kuchel; Ian E Alexander
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

2.  Complex management of a patient with a contiguous Xp11.4 gene deletion involving ornithine transcarbamylase: a role for detailed molecular analysis in complex presentations of classical diseases.

Authors:  Matthew A Deardorff; Himabindu Gaddipati; Paige Kaplan; Pedro A Sanchez-Lara; Neal Sondheimer; Nancy B Spinner; Hakon Hakonarson; Can Ficicioglu; Jaya Ganesh; Thomas Markello; Brett Loechelt; Dina J Zand; Marc Yudkoff; Uta Lichter-Konecki
Journal:  Mol Genet Metab       Date:  2008-06-03       Impact factor: 4.797

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.